Literature DB >> 31694708

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2 : National Harbor, MD, USA. 10 November 2019.

.   

Abstract

Year:  2019        PMID： 31694708      PMCID： PMC6833180          DOI： 10.1186/s40425-019-0764-0

Source DB:  PubMed          Journal:  J Immunother Cancer        ISSN： 2051-1426            Impact factor:   13.751


× No keyword cloud information.
  7 in total

Review 1.  Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination.

Authors:  Mizuho Sato-Dahlman; Christopher J LaRocca; Chikako Yanagiba; Masato Yamamoto
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

2.  New evidence for liver venous deprivation: safety and feasibility for extended liver resections.

Authors:  Jiang Zhang; Christian J Steib
Journal:  Ann Transl Med       Date:  2020-10

3.  Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.

Authors:  Tracy C Kuo; Amy Chen; Ons Harrabi; Jonathan T Sockolosky; Anli Zhang; Emma Sangalang; Laura V Doyle; Steven E Kauder; Danielle Fontaine; Sangeetha Bollini; Bora Han; Yang-Xin Fu; Janet Sim; Jaume Pons; Hong I Wan
Journal:  J Hematol Oncol       Date:  2020-11-30       Impact factor: 17.388

Review 4.  mRNA nanomedicine: Design and recent applications.

Authors:  Luke J Kubiatowicz; Animesh Mohapatra; Nishta Krishnan; Ronnie H Fang; Liangfang Zhang
Journal:  Exploration (Beijing)       Date:  2022-09-19

Review 5.  Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer.

Authors:  Enrica Marmonti; Jacqueline Oliva-Ramirez; Cara Haymaker
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

Review 6.  Exploring the food-gut axis in immunotherapy response of cancer patients.

Authors:  Edda Russo; Giulia Nannini; Monica Dinu; Giuditta Pagliai; Francesco Sofi; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

7.  Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).

Authors:  John Powderly; Alexander Spira; Shunsuke Kondo; Toshihiko Doi; Jason J Luke; Drew Rasco; Bo Gao; Minna Tanner; Philippe A Cassier; Anas Gazzah; Antoine Italiano; Diego Tosi; Daniel E Afar; Apurvasena Parikh; Benjamin Engelhardt; Stefan Englert; Stacie L Lambert; Sreeneeranj Kasichayanula; Sven Mensing; Rajeev Menon; Gregory Vosganian; Anthony Tolcher
Journal:  Clin Transl Sci       Date:  2020-12-26       Impact factor: 4.689
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.